Effect of tazobactam/piperacillin on intestinal bacterial flora: Studies in mice inoculated with four types of bacteria

Satoshi Iwata, Eiichi Isohata, Yoshiaki Kin, Takao Yokota, Yutaka Kusumoto, Yoshitake Sato, Hironobu Akita, Seiichiro Nanri, Tadao Oikawa, Intetsu Kobayashi, Keisuke Sunagawa

Research output: Contribution to journalArticle

Abstract

Tazobactam/piperacillin (TAZ/PIPC), an injectable combination antibiotic consisting of tazobactam (TAZ), a new β-lactamase inhibitor, with piperacillin (PIPC), an injectable penicillin antibiotic, in a ratio of 1: 4 (potency) was studied with regard to its effect on the intestinal flora of mice inoculated with four types of bacteria. A comparison was made with the efficacy of PIPC alone. In mice inoculated with four species of bacteria (Escherichia coli, Kitaken M, Enterococcus faecalis, Kitaken M, Bacteroides fragilis GKP 0001, and Bifidobacterium breve YIT 4006) in the intestinal lumen, TAZ/PIPC was administered i. m. at 100 mg/kg once daily for 5 consecutive days. From the day after the beginning of treatment, the cell counts of all species of bacteria examined began to decrease, and from the third day thereafter the cell counts were below detectable limits except for E. faecalis. Comparable results were obtained when PIPC alone at 100 mg/kg was administered in a similar manner. At 4 hours after completion of the final dose, the viable cell counts in the contents of various segments of the gastrointestinal tract (stomach, upper, middle and lower intestine, and large intestine) were lower for groups treated with TAZ/PIPC or PIPC than the control group for all segments examined. The PIPC levels in feces from the day after the beginning of treatment, and thereafter in large intestinal contents upon completion of the final dose, were 8.30-75.3 μg/g for the TAZ/PIPC group (excluding one sample in which the PIPC level was below the detectable limit) and 3.62-32.4 μg/g for the PIPC group (excluding one sample in which the PIPC level was below the detectable limit). The PIPC level in gastrointestinal contents was highest in the middle and lower segments of the intestine for both the TAZ/PIPC and the PIPC group. No detectable amount of TAZ was found in feces or in the gastrointestinal contents of each segment, with the exception of 2 samples. The minimum inhibitory concentrations (MIC) of TAZ/PIPC and PIPC were 6.25 μg/ml and 3.13 μg/ml for E. coli kitaken M, 3.13-6.25 μg/ml and 3.13 μg/ml for E. faecalis Kitaken M, 0.78-1.56 μg/ml and 3.13 μg/ml for B. fragilis GKP 0001, and 0.78 μg/ml and 0.39 μg/ml for B. breve YIT 4006. Neither the TAZ/PIPC nor the PIPC dosing group showed an increasing effect on the MIC of the 4 species tested.

Original languageEnglish
Pages (from-to)403-408
Number of pages6
JournalJapanese Journal of Chemotherapy
Volume44
Issue number6
Publication statusPublished - 1996
Externally publishedYes

Fingerprint

Piperacillin
Bacteria
Gastrointestinal Contents
Enterococcus faecalis
Bacteroides fragilis
Cell Count
Microbial Sensitivity Tests
Feces
Intestines
tazobactam drug combination piperacillin
Gastrointestinal Microbiome
Lower Gastrointestinal Tract
Escherichia coli
Injections
Upper Gastrointestinal Tract
Large Intestine
Penicillins
Stomach

ASJC Scopus subject areas

  • Pharmacology

Cite this

Iwata, S., Isohata, E., Kin, Y., Yokota, T., Kusumoto, Y., Sato, Y., ... Sunagawa, K. (1996). Effect of tazobactam/piperacillin on intestinal bacterial flora: Studies in mice inoculated with four types of bacteria. Japanese Journal of Chemotherapy, 44(6), 403-408.

Effect of tazobactam/piperacillin on intestinal bacterial flora : Studies in mice inoculated with four types of bacteria. / Iwata, Satoshi; Isohata, Eiichi; Kin, Yoshiaki; Yokota, Takao; Kusumoto, Yutaka; Sato, Yoshitake; Akita, Hironobu; Nanri, Seiichiro; Oikawa, Tadao; Kobayashi, Intetsu; Sunagawa, Keisuke.

In: Japanese Journal of Chemotherapy, Vol. 44, No. 6, 1996, p. 403-408.

Research output: Contribution to journalArticle

Iwata, S, Isohata, E, Kin, Y, Yokota, T, Kusumoto, Y, Sato, Y, Akita, H, Nanri, S, Oikawa, T, Kobayashi, I & Sunagawa, K 1996, 'Effect of tazobactam/piperacillin on intestinal bacterial flora: Studies in mice inoculated with four types of bacteria', Japanese Journal of Chemotherapy, vol. 44, no. 6, pp. 403-408.
Iwata, Satoshi ; Isohata, Eiichi ; Kin, Yoshiaki ; Yokota, Takao ; Kusumoto, Yutaka ; Sato, Yoshitake ; Akita, Hironobu ; Nanri, Seiichiro ; Oikawa, Tadao ; Kobayashi, Intetsu ; Sunagawa, Keisuke. / Effect of tazobactam/piperacillin on intestinal bacterial flora : Studies in mice inoculated with four types of bacteria. In: Japanese Journal of Chemotherapy. 1996 ; Vol. 44, No. 6. pp. 403-408.
@article{8b5bee6742bd48bf86e4ba50a35cdf07,
title = "Effect of tazobactam/piperacillin on intestinal bacterial flora: Studies in mice inoculated with four types of bacteria",
abstract = "Tazobactam/piperacillin (TAZ/PIPC), an injectable combination antibiotic consisting of tazobactam (TAZ), a new β-lactamase inhibitor, with piperacillin (PIPC), an injectable penicillin antibiotic, in a ratio of 1: 4 (potency) was studied with regard to its effect on the intestinal flora of mice inoculated with four types of bacteria. A comparison was made with the efficacy of PIPC alone. In mice inoculated with four species of bacteria (Escherichia coli, Kitaken M, Enterococcus faecalis, Kitaken M, Bacteroides fragilis GKP 0001, and Bifidobacterium breve YIT 4006) in the intestinal lumen, TAZ/PIPC was administered i. m. at 100 mg/kg once daily for 5 consecutive days. From the day after the beginning of treatment, the cell counts of all species of bacteria examined began to decrease, and from the third day thereafter the cell counts were below detectable limits except for E. faecalis. Comparable results were obtained when PIPC alone at 100 mg/kg was administered in a similar manner. At 4 hours after completion of the final dose, the viable cell counts in the contents of various segments of the gastrointestinal tract (stomach, upper, middle and lower intestine, and large intestine) were lower for groups treated with TAZ/PIPC or PIPC than the control group for all segments examined. The PIPC levels in feces from the day after the beginning of treatment, and thereafter in large intestinal contents upon completion of the final dose, were 8.30-75.3 μg/g for the TAZ/PIPC group (excluding one sample in which the PIPC level was below the detectable limit) and 3.62-32.4 μg/g for the PIPC group (excluding one sample in which the PIPC level was below the detectable limit). The PIPC level in gastrointestinal contents was highest in the middle and lower segments of the intestine for both the TAZ/PIPC and the PIPC group. No detectable amount of TAZ was found in feces or in the gastrointestinal contents of each segment, with the exception of 2 samples. The minimum inhibitory concentrations (MIC) of TAZ/PIPC and PIPC were 6.25 μg/ml and 3.13 μg/ml for E. coli kitaken M, 3.13-6.25 μg/ml and 3.13 μg/ml for E. faecalis Kitaken M, 0.78-1.56 μg/ml and 3.13 μg/ml for B. fragilis GKP 0001, and 0.78 μg/ml and 0.39 μg/ml for B. breve YIT 4006. Neither the TAZ/PIPC nor the PIPC dosing group showed an increasing effect on the MIC of the 4 species tested.",
author = "Satoshi Iwata and Eiichi Isohata and Yoshiaki Kin and Takao Yokota and Yutaka Kusumoto and Yoshitake Sato and Hironobu Akita and Seiichiro Nanri and Tadao Oikawa and Intetsu Kobayashi and Keisuke Sunagawa",
year = "1996",
language = "English",
volume = "44",
pages = "403--408",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "6",

}

TY - JOUR

T1 - Effect of tazobactam/piperacillin on intestinal bacterial flora

T2 - Studies in mice inoculated with four types of bacteria

AU - Iwata, Satoshi

AU - Isohata, Eiichi

AU - Kin, Yoshiaki

AU - Yokota, Takao

AU - Kusumoto, Yutaka

AU - Sato, Yoshitake

AU - Akita, Hironobu

AU - Nanri, Seiichiro

AU - Oikawa, Tadao

AU - Kobayashi, Intetsu

AU - Sunagawa, Keisuke

PY - 1996

Y1 - 1996

N2 - Tazobactam/piperacillin (TAZ/PIPC), an injectable combination antibiotic consisting of tazobactam (TAZ), a new β-lactamase inhibitor, with piperacillin (PIPC), an injectable penicillin antibiotic, in a ratio of 1: 4 (potency) was studied with regard to its effect on the intestinal flora of mice inoculated with four types of bacteria. A comparison was made with the efficacy of PIPC alone. In mice inoculated with four species of bacteria (Escherichia coli, Kitaken M, Enterococcus faecalis, Kitaken M, Bacteroides fragilis GKP 0001, and Bifidobacterium breve YIT 4006) in the intestinal lumen, TAZ/PIPC was administered i. m. at 100 mg/kg once daily for 5 consecutive days. From the day after the beginning of treatment, the cell counts of all species of bacteria examined began to decrease, and from the third day thereafter the cell counts were below detectable limits except for E. faecalis. Comparable results were obtained when PIPC alone at 100 mg/kg was administered in a similar manner. At 4 hours after completion of the final dose, the viable cell counts in the contents of various segments of the gastrointestinal tract (stomach, upper, middle and lower intestine, and large intestine) were lower for groups treated with TAZ/PIPC or PIPC than the control group for all segments examined. The PIPC levels in feces from the day after the beginning of treatment, and thereafter in large intestinal contents upon completion of the final dose, were 8.30-75.3 μg/g for the TAZ/PIPC group (excluding one sample in which the PIPC level was below the detectable limit) and 3.62-32.4 μg/g for the PIPC group (excluding one sample in which the PIPC level was below the detectable limit). The PIPC level in gastrointestinal contents was highest in the middle and lower segments of the intestine for both the TAZ/PIPC and the PIPC group. No detectable amount of TAZ was found in feces or in the gastrointestinal contents of each segment, with the exception of 2 samples. The minimum inhibitory concentrations (MIC) of TAZ/PIPC and PIPC were 6.25 μg/ml and 3.13 μg/ml for E. coli kitaken M, 3.13-6.25 μg/ml and 3.13 μg/ml for E. faecalis Kitaken M, 0.78-1.56 μg/ml and 3.13 μg/ml for B. fragilis GKP 0001, and 0.78 μg/ml and 0.39 μg/ml for B. breve YIT 4006. Neither the TAZ/PIPC nor the PIPC dosing group showed an increasing effect on the MIC of the 4 species tested.

AB - Tazobactam/piperacillin (TAZ/PIPC), an injectable combination antibiotic consisting of tazobactam (TAZ), a new β-lactamase inhibitor, with piperacillin (PIPC), an injectable penicillin antibiotic, in a ratio of 1: 4 (potency) was studied with regard to its effect on the intestinal flora of mice inoculated with four types of bacteria. A comparison was made with the efficacy of PIPC alone. In mice inoculated with four species of bacteria (Escherichia coli, Kitaken M, Enterococcus faecalis, Kitaken M, Bacteroides fragilis GKP 0001, and Bifidobacterium breve YIT 4006) in the intestinal lumen, TAZ/PIPC was administered i. m. at 100 mg/kg once daily for 5 consecutive days. From the day after the beginning of treatment, the cell counts of all species of bacteria examined began to decrease, and from the third day thereafter the cell counts were below detectable limits except for E. faecalis. Comparable results were obtained when PIPC alone at 100 mg/kg was administered in a similar manner. At 4 hours after completion of the final dose, the viable cell counts in the contents of various segments of the gastrointestinal tract (stomach, upper, middle and lower intestine, and large intestine) were lower for groups treated with TAZ/PIPC or PIPC than the control group for all segments examined. The PIPC levels in feces from the day after the beginning of treatment, and thereafter in large intestinal contents upon completion of the final dose, were 8.30-75.3 μg/g for the TAZ/PIPC group (excluding one sample in which the PIPC level was below the detectable limit) and 3.62-32.4 μg/g for the PIPC group (excluding one sample in which the PIPC level was below the detectable limit). The PIPC level in gastrointestinal contents was highest in the middle and lower segments of the intestine for both the TAZ/PIPC and the PIPC group. No detectable amount of TAZ was found in feces or in the gastrointestinal contents of each segment, with the exception of 2 samples. The minimum inhibitory concentrations (MIC) of TAZ/PIPC and PIPC were 6.25 μg/ml and 3.13 μg/ml for E. coli kitaken M, 3.13-6.25 μg/ml and 3.13 μg/ml for E. faecalis Kitaken M, 0.78-1.56 μg/ml and 3.13 μg/ml for B. fragilis GKP 0001, and 0.78 μg/ml and 0.39 μg/ml for B. breve YIT 4006. Neither the TAZ/PIPC nor the PIPC dosing group showed an increasing effect on the MIC of the 4 species tested.

UR - http://www.scopus.com/inward/record.url?scp=3042898287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042898287&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:3042898287

VL - 44

SP - 403

EP - 408

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 6

ER -